Evidence map›Paper›PMID 29619032›Full record

ArticleFrontiers in immunology2018

An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability

Paulo C M Urbano, Hans J P M Koenen, Irma Joosten, Xuehui He

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. The 'TNature reviews. Rheumatology · 2025
    Review
  8. Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.Journal of experimental & clinical cancer research : CR · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Paulo C M UrbanoLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Hans J P M KoenenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Irma JoostenLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Xuehui HeLaboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Radboud University Medical Center · NLQinghai Normal University · CNRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A crucial issue for Treg-based immunotherapy is to maintain a

Indexed as

Antibodies, Monoclonal, HumanizedAutocrine CommunicationCD28 AntigensCell ProliferationCells, CulturedDNA MethylationEpigenesis, GeneticForkhead Transcription FactorsGene ExpressionHumansImmunosuppressive AgentsInterleukin-17Receptors, Tumor Necrosis Factor, Type IISirolimusT-Lymphocytes, RegulatoryTumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedCD28 AntigensForkhead Transcription FactorsFOXP3 protein, humanImmunosuppressive AgentsInterleukin-17Receptors, Tumor Necrosis Factor, Type IISirolimusTGN-1412Tumor Necrosis Factor-alpharapamycinregulatory T cellsTNFαTreg stabilitytumor necrosis factor receptor 2tumor necrosis factor receptor 2 agonist antibody

Identifiers

PMID29619032
PMCPMC5871762
OpenAlexW2791195153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.